Metsera Inc.

16.82
-4.33 (-20.47%)
At close: Apr 04, 2025, 3:59 PM
17.18
2.14%
After-hours: Apr 04, 2025, 05:33 PM EDT
-20.47%
Bid 15
Market Cap 1.77B
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -2.03
PE Ratio (ttm) -8.29
Forward PE n/a
Analyst Buy
Ask 19.36
Volume 1,248,329
Avg. Volume (20D) 794,231
Open 20.41
Previous Close 21.15
Day's Range 16.29 - 20.44
52-Week Range 16.29 - 32.81
Beta 0.00

About MTSR

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New Y...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2025
Employees 74
Stock Exchange NASDAQ
Ticker Symbol MTSR
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for MTSR stock is "Buy." The 12-month stock price forecast is $47, which is an increase of 179.43% from the latest price.

Stock Forecasts